LifeMD, Inc. (LFMD)

LifeMD Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	163.56	152.55	119.03	92.88	37.29	12.47
Revenue Growth (YoY)	32.85%	28.15%	28.16%	149.04%	199.10%	49.79%
Cost of Revenue	19.29	18.9	18.67	18	8.86	2.53
Gross Profit	144.28	133.65	100.37	74.88	28.43	9.94
Selling, General & Admin	140.3	128.15	125.33	122.08	84.01	11.31
Other Operating Expenses	21.78	19.99	23.58	7.1	2.24	1.52
Operating Expenses	162.09	148.14	148.91	129.18	86.25	12.83
Operating Income	-17.81	-14.49	-48.55	-54.3	-57.82	-2.89
Interest Expense / Income	2.81	2.6	1.28	3.02	1.67	0.76
Other Expense / Income	2.31	3.08	-4.65	3.57	-0.96	-0.39
Pretax Income	-22.93	-20.17	-45.17	-60.89	-58.52	-3.26
Income Tax	0.43	0.43	0.36	0.01	0.12	-0.12
Net Income	-23.36	-20.6	-45.54	-60.9	-58.65	-3.14
Preferred Dividends	3.11	3.11	3.11	0.87	4.72	0
Net Income Common	-26.46	-23.7	-48.64	-61.77	-63.36	-3.14
Shares Outstanding (Basic)	39	34	31	27	14	10
Shares Outstanding (Diluted)	39	34	31	27	14	10
Shares Change	23.87%	9.45%	14.69%	89.20%	44.23%	12.00%
EPS (Basic)	-0.74	-0.70	-1.57	-2.29	-4.44	-0.32
EPS (Diluted)	-0.74	-0.70	-1.57	-2.29	-4.44	-0.32
Free Cash Flow	7.67	0.24	-31.83	-36.47	-12.53	0.25
Free Cash Flow Per Share	0.20	0.01	-1.03	-1.35	-0.88	0.03
Gross Margin	88.21%	87.61%	84.32%	80.62%	76.24%	79.75%
Operating Margin	-10.89%	-9.50%	-40.79%	-58.47%	-155.04%	-23.18%
Profit Margin	-16.18%	-15.54%	-40.86%	-66.51%	-169.90%	-25.16%
Free Cash Flow Margin	4.69%	0.15%	-26.74%	-39.26%	-33.60%	2.02%
EBITDA	-12.79	-10.97	-40.13	-57	-56.46	-2.16
EBITDA Margin	-7.82%	-7.19%	-33.71%	-61.37%	-151.39%	-17.35%
Depreciation & Amortization	7.33	6.6	3.77	0.87	0.4	0.34
EBIT	-20.12	-17.57	-43.9	-57.87	-56.86	-2.5
EBIT Margin	-12.30%	-11.52%	-36.88%	-62.31%	-152.46%	-20.04%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).